The Latest Cardiac and Vascular News
Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women ABBOTT PARK, Ill., Sept. 25, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration […]
– World’s smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects – Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart […]
New research found Abbott’s algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis This technology is the first machine learning developed algorithm that combines high […]
– TRILUMINATE Pivotal trial is the world’s first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation – There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid valves who are at high risk for surgery – Abbott’s […]
ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of […]
PARIS, May 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company’s minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a reduction of tricuspid regurgitation (TR) symptoms – caused by a leaky tricuspid heart valve […]
ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ — Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, the next-generation Confirm Rx™ insertable cardiac monitor (ICM), a paperclip-sized implantable […]
ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when added to current heart disease assessments.1 Using data from the Atherosclerosis […]
ABBOTT PARK, Ill., April 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019. First-quarter worldwide sales of $7.5 billion increased 2.0 percent on a reported basis and 7.1 percent on an organic* basis. Reported diluted EPS from continuing operations under GAAP was $0.38 in the first quarter. […]
NEW ORLEANS, March 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world’s largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint […]
